Allscripts President Lee Shapiro Joins Medidata Solutions Board of Directors

Global Clinical Trial Technology Company Attracts Key Leader in Healthcare IT

NEW YORK--(BUSINESS WIRE)--Medidata Solutions (NASDAQ: MDSO), a leading global provider of SaaS-based clinical development solutions, today announced the election of Lee Shapiro to its board of directors. Shapiro is president of Allscripts (NASDAQ: MDRX), the leading global provider of electronic health records and other technologies essential to creating a Connected Community of HealthTM.

"Medidata has established itself as a technology leader in clinical development and continues to drive the market with innovative products that improve decision effectiveness and bring insights to medical research," said Shapiro. "Medidata has earned a reputation among the physician community as a provider of exceptionally easy-to-use and easy-to-learn technology."

Shapiro brings significant experience directing strategic initiatives for Allscripts, including mergers and acquisitions, international expansion, business development and partnerships, and business activities in the areas of analytics and information services. Medidata will also benefit from Shapiro's experience serving on the boards of private and not-for-profit companies, including Physicians Interactive Holdings, LLC and the Gastro-Intestinal Research Foundation.

"Lee's insight into and broad experience with the healthcare community, as well as his impressive track record in building a world class organization, will be extremely valuable as we enter into our next stage of growth," said Tarek Sherif, chairman and CEO of Medidata Solutions. "Lee shares our passion for technology and vision for streamlining work processes that improve productivity - ultimately leading to more effective treatments, better outcomes and better health."

Prior to joining Allscripts in 2000, Shapiro was the chief operating officer of Douglas Elliman-Beitler, a commercial office management and development company, where he directed all business activities throughout the U.S. Shapiro also served as president of SES Properties, Inc., vice chairman of City Financial Bancorp and commercial lawyer at Barack, Ferrazzano, Kirschbaum, Perlman & Nagelberg.

Shapiro was appointed to the Economic Recovery Commission of the State of Illinois during its seating in 2009 to 2010 and holds a J.D. from The University of Chicago Law School.

About Allscripts

Allscripts (NASDAQ: MDRX) provides innovative solutions that empower all stakeholders across the healthcare continuum to deliver world-class outcomes. The company's Electronic Health Record, Computerized Physician Order Entry and other clinical, financial, connectivity and information solutions for hospitals, physicians and post-acute organizations are the essential technologies that enable a Connected Community of HealthTM. To learn more about Allscripts, please visit, Twitter, Facebook and YouTube.

About Medidata Solutions Worldwide

Medidata Solutions is a leading global provider of SaaS clinical development solutions that enhance the efficiency of customers' clinical trials. Medidata's advanced solutions lower the total cost of clinical development by optimizing clinical trials from concept to conclusion: from protocol development (Medidata Designer®), trial planning and management (Medidata Grants Manager®, Medidata CRO Contractor®), clinical portal (iMedidataTM), randomization and trial supply management (Medidata BalanceTM), monitoring (Medidata Rave Monitor, Medidata Rave Targeted SDV), safety events capture (Medidata Rave Safety Gateway), clinical data capture and management (Medidata Rave®) to advanced reporting and analytics (Medidata InsightsTM). Our diverse life science customer base spans biopharmaceutical companies, medical device and diagnostic companies, academic and government institutions, CROs and other research organizations, and includes more than 20 of the top 25 global pharmaceutical companies as well as organizations of all sizes developing life-enhancing medical treatments and diagnostics.

Suggested Articles

MicuRx nabbed $7.78 million from a nonprofit focused on antimicrobial resistance to push its third antimicrobial program into human trials.

The FDA has handed Scholar Rock a rare pediatric disease designation voucher, which can allow the biotech a speedy review of its SMA med.

The FDA has placed a phase 1/2 trial of Passage Bio’s GM1 gene therapy on clinical hold pending further assessment of the risk of its delivery device.